DZ Bank’s Sarepta Therapeutics SRPT Stock Holding History

DZ Bank’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-17,300	Closed	-$1.28M	–	1067
2018 Q1	$1.28M	Buy	+17,300	New	+$1.15M	0.01%	607

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

DZ Bank's SRPT Position: Q2 2018 in Review

DZ Bank sold out of Sarepta Therapeutics (SRPT) in Q2 2018, closing a stake of 17,300 shares — an estimated $1.28M sold.

DZ Bank first reported a position in SRPT in Q1 2018 and held it in 1 quarter. The position peaked at $1.28M in Q1 2018. 317 funds tracked by Wall St. Rank hold SRPT as of Q2 2018.

DZ Bank reported no remaining Sarepta Therapeutics position as of Q2 2018 after selling out during the quarter.
DZ Bank sold 17,300 Sarepta Therapeutics shares in Q2 2018, an estimated $1.28M.
DZ Bank first reported a position in Sarepta Therapeutics in Q1 2018 and held it in 1 quarter.
DZ Bank's Sarepta Therapeutics position peaked at $1.28M in Q1 2018.
317 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2018.

Based on DZ Bank's 13F filing for Q2 2018, filed 14 Aug 2018.